FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda has given "Apply" recommendation to Global Space IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 1 | 0 | 0 | 0 | 0 |
% | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Apply |
[Dilip Davda] No harm in giving this greedily priced offer a miss. Update 07/24/2017 After interaction with the merchant bankers, ipo valuation is done in line with global peers which trades at more than 8 times P/E of this company. Peers shown in prospectus are not comparable in true sense as they are not in healthcare segment. GSTL derives over 60% revenue from healthcare biz and is rapidly growing. FY 16 bottom-line decline is due to R and D and product development provisions. Management is confident of maintaining the growth in top and bottom lines. This is the fourth mandate from merchant banker and the last IPO opened at 5% premium to offer price on listing day. Based on this we have revised conclusion as: Conclusion : Investment may be considered for short to long term. (Subscribe) Read detail review...
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|